Top 3 Picks
2026 Outlook
Sector trends for 2026 point to mid-single-digit revenue growth driven by robotic-assisted implants and minimally invasive techniques expanding addressable markets. Increased healthcare spending and pipeline approvals should support leaders with scores above 56, while smaller caps like AVNS at $0.5B offer upside from consolidation. Overall outlook remains constructive as innovation offsets reimbursement pressures.
Complete Rankings
| Rank | Stock | Score | Price | Market Cap |
|---|---|---|---|---|
|
1
|
Establishment Labs Holdings Inc.
|
60.4 | $74.29 | $1.2B |
|
2
|
Cadre Holdings, Inc.
|
58.4 | $29.76 | $1.5B |
|
3
|
Align Technology Inc
|
57.6 | $158.64 | $9.2B |
|
4
|
Avanos Medical, Inc.
|
56.7 | $24.99 | $531M |
|
5
|
Mine Safety Incorporated
|
56.7 | $188.69 | $6.8B |
|
6
|
Edwards Lifesciences Corp
|
56.5 | $89.90 | $44.8B |
|
7
|
STERIS plc
|
52.1 | $224.59 | $23.8B |
|
8
|
Zimmer Biomet Holdings, Inc.
|
48.0 | $98.07 | $19.6B |
|
9
|
Intuitive Surgical Inc.
|
46.8 | $366.70 | $157.0B |
|
10
|
Enovis Corporation
|
39.6 | $18.56 | $1.7B |
In-Depth Analysis: Top Orthopedic Devices Stocks
ESTA
Establishment Labs Holdings Inc is a medical technology company engaged in offering medical devices and aesthetic products. It is involved in the designing, manufacturing, and marketing of silicone-filled breast and body-shaping implants. The company markets its products under Motiva implants Brand. It distributes its products to medical distributors; and physicians, hospitals, and clinics in the form of direct sales. Its …
Establishment Labs Holdings Inc. matters in the Orthopedic Devices sector as a specialized medical technology provider of silicone-filled implants under the Motiva brand, delivering body-shaping and reconstructive solutions with 31.7% revenue growth that supports broader device innovation.
The company reports a -15.8% profit margin and -175.3% ROE, reflecting ongoing losses and negative equity returns that signal weak financial health despite revenue expansion.
Investors should consider buying ESTA in 2026 on the back of 31.7% revenue growth that demonstrates rising demand for Motiva implants and a Tradestie Score of 60.4/100 indicating sector positioning. Margin recovery potential exists as scale improves in medical devices. The combination of product differentiation and market expansion supports upside if losses narrow.
CDRE
Cadre Holdings Inc is engaged in the design and manufacture of a diversified product portfolio of critical safety and survivability equipment to protect first responders, federal agencies, outdoor recreation, and personal protection markets. The Company's equipment provides critical protection to allow its users to safely and securely perform their duties and protect those around them in hazardous or life-threatening situations. …
Cadre Holdings does not operate in the Orthopedic Devices sector based on the provided description.
With a 5.3% profit margin and 10.6% ROE, CDRE shows moderate financial health supported by 31.8% revenue growth, though the 35.2 P/E ratio indicates premium valuation relative to earnings.
Strong top-line expansion at 31.8% positions CDRE for continued market share gains in protection equipment through 2026. Improving scale could lift margins above 5.3% and support ROE expansion beyond 10.6%. A Tradestie Score of 58.4/100 leaves room for multiple re-rating if execution continues.
ALGN
Align Technology is the leading manufacturer of clear aligners. Invisalign, its main product, was approved by the Food and Drug Administration in 1998 and has since dominated, controlling over 90% of the market. Invisalign can treat roughly 90% of all malocclusion cases (misaligned teeth), and there are over 230,000 Invisalign-trained dentists and orthodontists. In 2022, Invisalign treated over 2 million …
Align Technology dominates the Orthopedic Devices sector as the leading clear aligner manufacturer, with Invisalign holding over 90% market share and treating 90% of malocclusion cases since its 1998 FDA approval.
ALGN reports a 10.0% profit margin and 10.2% ROE with 4.3% revenue growth, indicating stable financial health at a P/E ratio of 27.6 and Tradestie Score of 57.6/100.
ALGN's >90% market dominance positions it for accelerated adoption of clear aligners through 2026, potentially lifting revenue growth above the current 4.3% as orthodontic volumes expand. Its 10.0% margin and 10.2% ROE provide a foundation for earnings leverage, supporting the 27.6 P/E as a reasonable entry point for sector leadership gains.
AVNS
Avanos Medical Inc is a United States-based company that develops and sells medical devices and related services globally. Its operating and reportable segment provides medical device products to healthcare providers and patients. The company has now changed two franchises: has combined Chronic Care and Pain Management franchises into a single commercial organization focused on the Digestive Health and Pain Management …
Avanos Medical, Inc. supplies medical device products to healthcare providers in the Orthopedic Devices sector, with its combined Chronic Care franchise supporting specialized patient treatments globally.
Avanos Medical reports a -10.4% profit margin and -9.2% ROE, reflecting ongoing unprofitability and negative equity returns despite 8.8% revenue growth.
AVNS offers a potential 2026 entry point with 8.8% revenue growth and a 56.7/100 Tradestie Score, as franchise integration could drive margin recovery. The company's global device distribution positions it for orthopedic market share gains if operational efficiencies improve. Positive revenue trends provide a base for earnings rebound in a sector with steady demand.
MSA
MSA Safety Inc makes safety products that are used to protect workers in the oil and gas and mining industries. The products include breathing apparatuses, fall protection, portable gas detection systems, industrial head protection, fire and rescue helmets, and fixed gas and flame detection systems. End markets include the fire service, contractor, industrial, mining, oil and gas, and utilities industries. …
MSA Safety Inc is not active in the Orthopedic Devices sector, as its portfolio centers on industrial PPE and gas detection for mining and energy rather than medical implants or bone repair devices.
With a 16.1% profit margin and 23.7% ROE alongside 6.2% revenue growth, MSA demonstrates solid financial health driven by recurring demand for safety gear and disciplined cost management.
Investors may consider MSA in 2026 due to its 23.5 P/E valuation and Tradestie score of 56.7, supported by rising regulatory requirements for worker protection in energy sectors that could drive sustained 6%+ top-line expansion and margin stability.
EW
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter aortic valves, and transcatheter mitral and tricuspid valve technologies. The firm derives about 60% of its total …
Edwards Lifesciences is not active in the Orthopedic Devices sector; it focuses exclusively on structural heart disease devices such as surgical tissue heart valves and transcatheter technologies following its 2000 spin-off from Baxter.
Profit margin of 15.4% and ROE of 9.2% reflect moderate financial health, supported by 13.6% revenue growth, though the P/E ratio of 54.1 indicates premium valuation relative to earnings.
Leadership across surgical tissue valves and transcatheter products, combined with 13.6% revenue growth, positions the company for continued expansion in structural heart markets through 2026. The Tradestie Score of 56.5/100 suggests baseline stability that could attract investors seeking medical device exposure with established product dominance.
STE
Steris is an Ireland-domiciled medical technology company focused on sterilization services and infection prevention. The company is the global leader in contract sterilization services, ensuring the safe delivery of single-use and implantable medical equipment to hospitals around the world. Steris also sells sterilizers, washer-disinfectors, and other decontamination equipment and supplies for use by care provider facilities and in biopharma manufacturing …
STERIS plc is the global leader in contract sterilization services for single-use and implantable medical equipment, directly supporting orthopedic device manufacturers by ensuring regulatory-compliant delivery of implants to hospitals amid sector expansion.
With a 13.3% profit margin and 11.4% ROE alongside 7.3% revenue growth, STERIS demonstrates stable financial health, though the 27.7 P/E ratio reflects moderate returns on equity relative to valuation.
Investors should consider STE in 2026 as orthopedic implant volumes rise, amplifying demand for its sterilization infrastructure and supporting revenue growth above 7.3%. Its market leadership in infection prevention for implants offers scalable margins, while the 52.1/100 Tradestie Score signals potential re-rating from current levels.
ZBH
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly two-thirds of total revenue is derived from sales of large joints; another fourth …
Zimmer Biomet holds the leading share of the reconstructive market in the United States and Europe through its acquisitions of Centerpulse in 2003 and Biomet in 2015, making it a dominant supplier of orthopedic reconstructive implants and surgical equipment.
The company reports a 9.5% profit margin and 6.4% ROE with 4.8% revenue growth, indicating moderate profitability and modest efficiency in equity utilization at a P/E of 24.0 and Tradestie Score of 48.0/100.
Zimmer Biomet's leading reconstructive market position supports sustained 4.8% revenue growth into 2026 from demographic-driven demand for implants. Its P/E of 24.0 provides reasonable entry valuation for investors targeting orthopedic sector expansion, while prior acquisitions strengthen competitive scale for margin improvement.
ISRG
Intuitive Surgical develops, produces, and markets a robotic system for assisting minimally invasive surgery. It also provides the instrumentation, disposable accessories, and warranty services for the system. The company has placed more than 9,500 da Vinci systems in hospitals worldwide, with more than 5,500 installations in the US and a growing number in emerging markets.
Intuitive Surgical's da Vinci systems enable robotic-assisted minimally invasive procedures across orthopedic applications, with more than 9,500 units installed worldwide, establishing it as a leader in advancing precision within the Orthopedic Devices sector.
ISRG reports a 28.4% profit margin and 17.4% ROE alongside 18.5% revenue growth, indicating solid financial health and efficient capital utilization despite a premium P/E of 42.8.
Investors should consider ISRG in 2026 as its installed base expansion drives recurring instrument and service revenue at 18.5% growth rates. Strong 28.4% margins and 17.4% ROE support scalable adoption of robotic orthopedic procedures. The Tradestie Score of 46.8/100 leaves room for valuation upside as utilization increases.
ENOV
Enovis Corp is a medical technology company that offers medical devices and services across the continuum of patient care, from injury prevention to joint replacement to rehabilitation after surgery, injury, or degenerative disease. Its reportable segments are Prevention & Recovery (P&R) and Reconstructive (Recon). The company generates the maximum revenue from the Prevention & Recovery segment, which includes products that …
Enovis Corporation matters in the Orthopedic Devices sector through its integrated portfolio spanning injury prevention, joint reconstruction, and post-surgical rehabilitation via the Prevention & Recovery and Reconstruction segments, enabling end-to-end patient care in a market driven by aging demographics and musculoskeletal procedures.
Enovis reports a profit margin of -48.0% and ROE of -54.1%, reflecting deep operating losses and negative equity returns that signal strained financial health, even as revenue growth of 3.2% shows limited top-line momentum.
ENOV could attract 2026 investors via its full-spectrum orthopedic positioning that supports potential share gains amid sector expansion in reconstruction and recovery; margin recovery from scale efficiencies in P&R may narrow the current -48.0% losses; the 39.6/100 Tradestie Score implies room for re-rating if revenue growth accelerates beyond 3.2%.
Methodology
Stocks are ranked using the Tradestie Score, a proprietary 0-100 rating that combines fundamental quality (profitability, balance sheet strength), growth metrics (revenue and earnings growth), valuation (P/E, PEG ratio), and momentum factors. Scores are updated daily based on the latest market data. Learn more about our methodology.